



August 1, 2018

Mercy Hospital Springfield Attn: Sarah Asperger, MHA, Vice President, Payor Relations and Contracting 3265 S. National Suite 200 Springfield, MO 65807

Effective: August 1, 2018

Aetna to require additional coding for 340B acquired drugs

Effective January 1, 2018 the Centers for Medicare and Medicaid (CMS) established two Healthcare Common Procedure Coding System (HCPCS) Level II modifiers to identify 340B-acquired drugs:

- Modifier JG Drug or biological acquired with 340B drug pricing program discount
- Modifier TB Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes.

What is being requested:

Effective July 1, 2018, Aetna will require that all Commercial and Medicare outpatient drugs purchased under the 340B program be billed using the appropriate modifier, JG or TB.

Who will this impact:

Aetna will follow CMS reporting requirements as it relates to which modifier should be billed depending upon its hospital type and the Outpatient Prospective Payment System (OPPS) drug status indicator. Please see attached link for additional information as it relates to your facility.

Have questions or need information?

See CMS FAQ provided in the below link:

www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/Billing-340B-Modifiers-under-Hospital-OPPS.pdf For other general information, you may call:

Aetna claims, benefit or eligibility questions:

- 1-800-624-0756 HMO and Medicare Advantage
- 1-888-632-3862 All other plans

Coventry claims, benefit or eligibility questions:

- 1-800-788-8445 Commercial plans in Eastern Pennsylvania
- 1-800-290-0190 Advantra plans

Sincerely,

Greg Killinger

Vice President, Network Management

Diez Killingen

Aetna

Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna).

©2018 Aetna Inc.

tA-19717